Ligand Pharmaceuticals has turned a series of antibody discovery acquisitions into a growing business unit. Ligand now wants to spin it off as a separate company, but that new company will compete head to head against established antibody players AbCellera and Adimab.
Bionano Genomics is acquiring genomics software firm BioDiscovery in a $90 million cash and stock deal. While both companies provide genomics analysis solutions, Bionano said combining its technology with BioDiscovery’s software will provide the integrated offering that many labs want.
Health care professionals can refer patients to the best options for diagnostic imaging covered by Medicare to give more people the medical assistance they need without extra financial stress.
Atavistik Bio is one of several companies discovering and developing drugs that work by allostery, binding to less obvious sites of a target protein. Acting CEO John Josey said the startup aims to stand apart with its focus on understanding metabolic interactions, a path less trodden by others in allosteric drug discovery.
Founded by former hedge fund manager Vivek Ramawamy, Roivant Sciences set out to redefine drug development by acquiring overlooked drugs and advancing their development. The merger deal that will take it public reveals how much new technology changed the company's vision and its strategy.
Plant-based drug discovery may be tens of thousands of years old, but in 2021, it feels exciting, rich, and full of potential. Companies are rapidly building scalable databases with hundreds of thousands of unique chemicals and their links to biological signatures.
Relay Therapeutics has its own technology that applies artificial intelligence and machine learning techniques to drug discovery. Its $85 million acquisition of ZebiAI gives it another technology that applies ML to DNA-encoded libraries and predicts the small molecules with the potential to drug proteins.
Finding the best analytics tools for health care revenue management can revolutionize operational processes. Compare the leading software options to discover helpful team resources.
Roivant Sciences is expanding its drug discovery and design capabilities via a stock deal to acquire Silicon Therapeutics. The Boston startup uses physics-based modeling to simulate proteins and the small molecules that bind to them.
The deal with Roche subsidiary Genentech is likely not the last for Genesis Therapeutics, which is based on AI research undertaken at Stanford. Such partnerships are potentially lucrative for drug-discovery startups.
The six-year-old Google-backed company was founded by three MIT physicists and hopes to use its technology to make drug discovery faster and less cumbersome by combining physics, AI and cloud computing.
Repurpose.AI, a San Diego-based drug discovery startup, struck a partnership with LEO Pharma to identify potential dermatology drug candidates. The startup searches through a library of drugs that have passed Phase I trials, but might not have been commercialized, to find promising candidates.
This webinar will explore how a banking platform approach could be the resource for your company.
The question of who owns the intellectual property to a drug born inside a computer came up in a panel discussion at a recent life sciences law symposium.
Drug discovery software company Schrödinger raised $232 million in its IPO, which closed Monday. The company’s stock was trading at $27.22 on Tuesday.
Another AI drug discovery firm has sprung up in Silicon Valley with seed investors, including Andreessen Horowitz, kicking in $4.1 million.
The partnership will enable researchers from the Swiss drugmaker to use AI to find insights hidden in large amounts of data while also finding new approaches to personalized medicine in certain diseases and the manufacture of cell and gene therapies.
The company has signed an initial partnership with Genentech that will focus on understanding the genetic components that are related to a person's risk of developing ocular diseases like macular degeneration.